

Glaucoma Filtration Surgery using Amniotic Membrane Transplantation

Keith Barton,^{1,2} Donald L. Budenz,¹ Peng T. Khaw,² and Scheffer C. G. Tseng¹

PURPOSE. To investigate the potential use of amniotic membrane transplantation (AMT) in the construction of glaucoma filtering blebs.

METHODS. Twenty-four albino rabbits underwent glaucoma filtration surgery in one eye. In alternate cases, the conjunctival flap was replaced with AMT. Postoperative examination data were grouped into three time points. Six animals with AMT and six filtration surgery-controls were euthanized at each of two postoperative time points, and tissue was obtained for histologic examination. Conjunctival biopsies were explanted for estimation of fibroblast outgrowth.

RESULTS. Bleb formation was observed in all eyes, and amniotic membranes were epithelialized after 11.2 ± 2.48 (mean \pm SD) days. Throughout the study IOPs were significantly lower in operated than unoperated fellow eyes. Between postoperative days 11 and 16 (the middle time point), the percentage IOP reduction in AMT eyes was significantly greater than in filtration surgery controls ($P = 0.014$), though not at other time points. Filtration surgery survival was significantly longer in the AMT group (22.3 ± 3.8 days; mean \pm SE) than in "No AMT" controls (14.0 ± 1.6 days; $P = 0.035$). In tissue culture, significantly less fibroblast outgrowth occurred from AMT explants when compared with unoperated conjunctiva ($P = 0.01$) between postoperative days 3 and 9 (the early time point). Amniotic membrane transplants were intact on histologic examination after 14 days but were associated with considerable granulomatous inflammation. After 36 days, the ocular surfaces remained clinically intact, but lysis of AMT was noted histologically.

CONCLUSIONS. AMT exhibits potential as an alternative tissue to conjunctiva in the construction of glaucoma filtration blebs. The healing response as demonstrated by fibroblast outgrowth is retarded when compared with conventional conjunctival closure. The improvement in bleb survival must be weighed against the potential for complications related to delayed heal-

ing. In rabbits, human amniotic membrane elicited a late xenograft reaction, leading to granulomatous inflammation and dissolution of the membrane. (*Invest Ophthalmol Vis Sci.* 2001; 42:1762-1768)

The formation of an adequate bleb after filtration surgery may be compromised by subconjunctival fibrosis, which obstructs aqueous outflow from the operation site. To combat this effect, antifibrotic drugs such as 5-fluorouracil¹⁻⁹ and mitomycin C¹⁰⁻¹⁷ are commonly used at the time of filtration surgery. However, these drugs may also influence the integrity of the conjunctival barrier, resulting in a thin-walled avascular drainage bleb.¹⁸⁻²¹ The end result is often poor epithelialization and increased susceptibility to leakage and hypotony^{3,22-24} or infection,²⁵⁻²⁸ sometimes months or years after surgery. Conversely, when adjunctive antifibrotics are not used, drainage surgery in certain patient groups, such as those who have had previous conjunctival surgery, is more likely to result in failure than success.⁷

Replacement of conjunctiva over the filtration surgery site with a tissue that heals less aggressively is an alternative approach to the reduction of subconjunctival healing in glaucoma filtration surgery. Amniotic membrane transplantation (AMT) has been used recently in the reconstruction of the ocular surface after pterygium excision,²⁹ in nonhealing corneal epithelial defects,³⁰⁻³² in cicatrizing conjunctival disease^{33,34} and to retard corneal neovascularization in patients with limbal stem cell deficiency.³⁵ Amniotic membrane exhibits a number of characteristics that might be of benefit in filtering bleb construction, that is, good epithelialization, good integration with surrounding tissue, a low-healing response, suppression of TGF- β activity,³⁶ poor immunogenicity, and yet a high hydraulic conductivity.³⁷ The purpose of this study was to investigate the potential usefulness of AMT in the construction of glaucoma filtering blebs in an adapted animal filtration surgery model.

METHODS

Approval for the study was obtained from the Animal Care and Use Committee of the University of Miami. Experiments were performed in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

Animals

Twenty-four female New Zealand White rabbits, weighing 2 to 4 kg, were used.

Anesthesia for Surgery

Animals were anesthetized with an intramuscular (dorsal surface of thigh muscle) injection of xylazine (7 mg/kg) and ketamine (14 mg/kg). The anesthesia level was monitored by blink reflex and toe withdrawal reflex.

Surgery

After adequate anesthesia, the left eye of each animal was prepared and draped in a sterile manner. No traction suture was used. A temporal

From the ¹Bascom Palmer Eye Institute, University of Miami School of Medicine, Florida, and ²Moorfields Eye Hospital, London, United Kingdom.

Supported by the TFC Frost Charitable Trust, London, and the Iris Fund for Prevention of Blindness, London, United Kingdom (KB); by National Institutes of Health, National Eye Institute, Bethesda, Maryland, Grant EY06819 (SCGT); and by Research to Prevent Blindness, New York, New York (SCGT and DLB). KB and PTK also receive support from the National Health Service (NHS) Executive, London, United Kingdom. The views expressed in this publication are those of the authors and not necessarily of the NHS Executive.

Submitted for publication September 25, 2000; revised February 14, 2001; accepted March 12, 2001.

Commercial relationships policy: P. SCGT has obtained a patent of the method of preparation and clinical uses of human amniotic membrane and has a financial interest in Bio-Tissue, a tissue bank that procures, processes and distributes amniotic membrane for research and clinical use.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Corresponding author: Keith Barton, Moorfields Eye Hospital, 162 City Road, London EC1V 2PD, UK. keith1barton@cs.com

approach was made in each case for ease of access. The nictitating membrane was not removed.

Twenty-four animals underwent filtration surgery using a trans-scleral cannula to maintain patency of the sclerostomy.³⁸ Animals were allocated a study number from 1 to 24 according to chronological order of surgery. The filtration surgery procedure is described below. The two study groups differed in the method of conjunctival closure. In odd-numbered animals a 5-mm fornix-based conjunctival flap was prepared. At the conclusion of the procedure, conjunctival closure was obtained by reapposition of the conjunctival flap to the limbus using one 10/0 monofilament nylon suture at each corner and one mattress suture in the middle. Extra interrupted sutures were added as required to produce a watertight seal. In even-numbered animals, a 5-mm square limbus-based conjunctival flap was prepared and excised before performing the filtration surgery. At the conclusion of the procedure, closure was achieved using AMT cut to fit the conjunctival defect. The method of AMT procurement, preparation, and storage is outlined below. AMT was secured using a 10/0 monofilament nylon continuous suture along the conjunctival interface with interrupted sutures at each limbal corner and a mattress suture in the center of the limbal interface.

Filtration Surgery Model

The adapted filtration surgery model used was as originally reported by Cordeiro,³⁸ using a trans-scleral cannula to maintain a patent sclerostomy and prevent scleral healing. Briefly, the conjunctival flap was prepared as described above, a short tunnel was then fashioned from sclera into the anterior chamber just behind the corneo-scleral limbus using a 23-gauge hypodermic needle. A 22-gauge intravenous cannula (Abbocath, Sligo, Republic of Ireland) was then introduced via the same track, and the trocar was removed. The tube was placed in the anterior chamber with the internal opening close to the visual axis to avoid plugging of the tube with iris, while also avoiding corneal touch. The tube was then fixed to sclera using a single 9/0 nylon interrupted suture (Ethicon, Somerville, NJ). At this point the ocular surface was closed using either the AMT or fornix-based conjunctival flap as described above.

An anterior chamber paracentesis was performed with a 30-gauge hypodermic needle, and the anterior chamber was reformed with balanced salt solution to confirm the presence of a patent sclerostomy and inflate the bleb. At the conclusion of the procedure dexamethasone ophthalmic ointment was applied to the eye. Figures 1A through 1E demonstrate the stages of the surgical procedure.

Amniotic Membrane

Preserved human amniotic membrane was obtained, preserved, and stored as previously described.²⁹ Briefly, human placenta was obtained shortly after elective Cesarean section when human immunodeficiency virus, hepatitis B and C virus, and syphilis had been excluded by serologic testing. Under a lamellar flow hood, the placenta was cleaned of clots with sterile Earle's balanced salt solution (Life Technologies, Inc., Gaithersburg, MD) containing 50 mg/ml penicillin, 50 mg/ml streptomycin, 100 mg/ml neomycin, and 2.5 mg/ml amphotericin B (Life Technologies Inc.). The amnion was separated from chorion by blunt dissection. The isolated amnion was then flattened onto nitrocellulose paper (Bio-Rad, Gainesville, FL) with epithelium/basement membrane surface up. The nitrocellulose combined with amniotic membrane was then cut into 3 × 4-cm² rectangles and stored at -80°C in a sterile vial containing Dulbecco's modified Eagle medium (Life Technologies Inc.) and glycerol (Baxter Health Care Corp., Stone Mountain, GA) at the ratio of 1:1 (vol/vol) before transplantation.

Postoperative Examinations

Postoperatively, each eye received dexamethasone ointment daily for 3 days. Postoperative examinations were carried out twice weekly under general anesthesia (xylazine/ketamine as above). The IOP was measured in each eye on each occasion using a Tonopen XL (Mentor,




FIGURE 1. Stages of filtration surgery with amniotic membrane transplantation (A through E). Preoperative appearance (A) and reflection of limbus-based conjunctival flap (B). (C) Insertion of trans-scleral intravenous cannula to prevent scleral closure. (D) After suturing the cannula to sclera, the external excess length of cannula is removed. (E) Transferring amniotic membrane from nitrocellulose membrane to the ocular surface. Amniotic membrane blebs (F and G) and control bleb (H) at the conclusion of surgery.

Norwell, MA) with readings repeated to obtain a <5% disparity between the highest and lowest readings. The frequency of aqueous leakage from conjunctiva/AMT after surgery, and the degree of AMT epithelialization was examined by staining the bleb surface with 2% fluorescein drops (Chauvin Pharmaceuticals Ltd., Romford, United Kingdom). The stained surface was observed for the presence of aqueous leakage and an epithelial defect during each examination.

Euthanasia and Tissue Harvesting

Animals 1 to 12 were euthanized 14 days after surgery (early time point) and 13 to 24 at approximately 30 days (late time point). Euthanasia was performed by initially anesthetizing the animals using xylazine/ketamine as described above. This was followed by an intravenous overdose of pentobarbital sodium (Euthasol; Delmarva Laboratories Inc., Midlothian, VA) while the animals were anesthetized.

The left eyes were removed immediately after death, preserving the AMT and bulbar conjunctiva. The enucleated eyes were placed in a 10-cm Petri dish under sterile conditions, and biopsies of conjunctiva/tenons and AMT taken using a 1.5-mm-diameter trephine as indicated in Figure 2. Four zones were identified for biopsy purposes: (1) unop-




FIGURE 2. Diagram illustrating biopsy sites. (A) AMT eyes and (B) control eyes. (1) unoperated conjunctiva (180° from filtration surgery site), (2) peri-AMT conjunctiva, (3) AMT, and (4) conjunctival bleb biopsy from control filtration surgery.

erated conjunctiva (180° from the site of surgery); (2) conjunctiva adjacent to amniotic membrane; (3) AMT; and (4) conjunctiva from the bleb area in control operations.

Conjunctival biopsy specimens were explanted immediately into tissue culture as described below.³⁹ The remaining amniotic membranes/conjunctival flaps were then excised with underlying sclera and surrounding conjunctiva attached and placed in 10% formol saline for histologic examination.

Conjunctival/Amniotic Membrane Explants

Conjunctival and amniotic membrane biopsies were explanted individually in each well of 12-well tissue culture plates (Costar, Cambridge, MA) in tissue culture medium containing Dulbecco's modified Eagles's medium/F-12/M-199/Hepes buffer (Gibco, Grand Island, NY) with 20% fetal calf serum (Gibco) as previously described.³⁹ Each explant was incubated initially in one drop of tissue culture medium at 37°C in a humidified atmosphere containing 5% CO₂. After approximately 1 hour, 1 ml of tissue culture medium was gently added to each well so as not to disturb the explants.

Explants were examined daily for fibroblast and epithelial cell outgrowth and photographed using a microscope-mounted 35-mm camera. After 14 days the monolayers were fixed in 100% methanol and stained with Gram Crystal Violet (Bacto; Difco Laboratories, Detroit, MI). After fixation, wells were individually photographed, and a series of 5 × 7-inch black and white prints was produced, each representing one well. The area of fibroblast outgrowth from each explant was assessed from its respective photograph by planimetry using a Kurta 1212 Summasketch Tablet Board and Sigmascan software (SPSS Inc., Chicago, IL). The magnification factor was calculated from the ratio of the diameter of a well on photographic print to the actual well diameter and the actual area of outgrowth expressed in cm².

Histology

Samples taken for histology were mounted in paraffin, sectioned, mounted, stained with either periodic acid-Schiff (PAS) or Masson-Trichrome, and examined by light microscopy.

PAS-stained sections were examined by a masked observer (consultant ophthalmic pathologist) for the presence and state of amniotic membrane (whether intact or fragmented), presence of histologically complete epithelialization, and degree of underlying inflammation.

Outcome Measures

Primary outcome measures included bleb formation, rate of epithelialization, frequency of aqueous leakage, degree and duration of IOP lowering, and the frequency of postoperative complications. The rate of epithelialization of AMT, as judged by lack of fluorescein staining by unepithelialized membrane, was calculated as the time (days) from surgery to complete epithelialization.

IOP lowering in the operated eye was calculated as the percentage lowering in comparison with the unoperated eye. The time to filtration surgery failure was defined as the time to normalization of the IOP when compared with the unoperated eye. Postoperative complications such as bleb infection, hypotony, and intraocular hemorrhage were also recorded.

Secondary outcome measures included quantification of fibroblast outgrowth from AMT biopsies versus conjunctival biopsies in tissue culture, the qualitative histologic state of the amniotic membrane postoperatively, and the pattern of subconjunctival/submembrane inflammatory response.

Statistical Measurements

Statistical calculations were performed using SPSS for Windows release 8.0 (SPSS Inc.). Means were compared using an unpaired two-tailed Student's *t*-test. Filtration surgery survival analysis was performed using Kaplan-Meier survival analysis and the log rank test.

RESULTS

Primary Outcome Measures

Bleb Formation, Epithelialization of Amniotic Membranes, and Aqueous Leakage from Blebs. In both groups, bleb formation was observed clinically in all eyes at the conclusion of surgery (Figs. 1F through 1H). No epithelial defects were noted on the bleb surface of filtration surgery control eyes on the first postoperative day. In the AMT group, all blebs were noted to have epithelial defects over the entire AMT at the first postoperative examination. Clinical epithelialization of amniotic membranes had occurred (as judged by absence of staining of membrane with 2% fluorescein) by 11.2 ± 2.5 days (mean \pm SD), excluding one case that was not fully epithelialized at harvesting on day 14. In this and one other AMT case, persistent aqueous leakage was noted at the limbal edge of the membrane. This was rectified in later cases by a change in suturing technique (i.e., the addition of extra horizontal mattress sutures at the limbus to prevent leakage).

Epithelialization was observed to occur in all AMT cases by creeping ingrowth from both limbal and conjunctival interfaces (Fig. 3), except in the case that had failed to epithelialize by day 14. In that particular case, epithelialization occurred from the conjunctival interface but not from the leaking limbal edge. Similarly slow vascularization of membranes occurred over the study period by ingrowth from all sides (Fig. 3).

Lowering of IOP Relative to Unoperated Eye and Filtration Surgery Survival. The IOP-lowering effect of surgery was quantified by measuring the percentage reduction in IOP in the operated eye when compared with the unoperated eye. This method was used to minimize the influence of anesthesia on the IOP reduction. IOPs were measured during nine postoperative examinations throughout the study, and results averaged for each animal to give three broad time points; days 3 to 9 (early), days 11 to 16 (middle), and days 17 to 38 (late).




FIGURE 3. Epithelialization and vascularization. (A and B) An avascular amniotic membrane bleb 3 days after surgery (A) and stained with fluorescein (B) to demonstrate epithelial defect. (C) The same bleb at 24 postoperative days showing complete vascularization. There was no epithelial defect at this stage. (D and E) Control bleb at 5 days (D) and 28 days (E) after surgery.

Values for percentage reduction and actual reduction in terms of mm Hg are presented for comparison (Table 1).

Throughout the study IOPs were significantly lower in all operated eyes than in unoperated eyes. In the early postoperative period (days < 10), there was no significant difference in IOP-lowering between the two study groups (20.7% ± 5.2% [mean ± SE] for AMT, 17.7% ± 5.8% for filtration surgery controls). From days 11 to 16 the percentage IOP reduction in AMT eyes was significantly greater than in filtration surgery controls (21.7% ± 6.04% for AMT, 2.00% ± 4.3% for controls; *P* = 0.014). Thereafter (days 17–38) there was no significant difference in IOP reduction between groups (8.4% ± 3.5% for AMT, 10.1% ± 4.4% for controls), by which time 50% of the animals had already been euthanized, and therefore remaining numbers were smaller (Table 1).

The survival time of each filtration procedure was defined as the time (days) from operation to normalization of the IOP (i.e., IOP in operated eye under anesthesia equal to that in unoperated eye) on repeated measurement at one time point.

TABLE 1. Percentage versus Absolute Reduction in IOP

Time Point	Absolute Reduction in IOP Relative to Unoperated Eye (mmHg)			Reduction in IOP Relative to Unoperated Eye (%)		
	Control	AMT	<i>P</i>	Control	AMT	<i>P</i>
Days 3–9	2.32 ± 0.74	2.47 ± 1.10	NS	17.6 ± 5.8	20.8 ± 5.2	NS
Days 11–16	0.25 ± 0.62	2.20 ± 0.50	0.023	2.00 ± 4.3	21.7 ± 6.0	0.014
Days 17–38	2.01 ± 0.62	1.29 ± 0.71	NS	10.1 ± 4.4	8.4 ± 3.5	NS

Values are mean ± SE. NS, not significant.

Trabeculectomy Survival




FIGURE 4. Kaplan-Meier survival curve of AMT versus control (no AMT) procedures. Filtration surgery failure was recorded when the IOP was normalized with respect to the fellow eye (*P* = 0.035, Log rank).

The filtration surgery survival time for the AMT group was 22.3 ± 3.8 days (mean ± SEM), compared with 14.0 ± 1.6 days in controls (*P* = 0.035, log-rank test; Fig. 4).

Complications. Ocular hypotony was defined as an IOP < 5 mm Hg. In one eye hypotony was documented (one of the two leaking eyes) with an IOP of 3 mm Hg, but on only one examination. No episodes of severe intraocular hemorrhage or postoperative intraocular infection were documented.

Secondary Outcome Measures

Fibroblast Outgrowth from AMT Biopsies versus Conjunctival Biopsies in Tissue Culture. In tissue culture, no fibroblast outgrowth had occurred from AMT explants harvested at the early time point after 14 days in tissue culture (Table 2). This was significantly less than in conjunctiva taken 180° from the site of surgery (*P* = 0.003). At the late time point, some fibroblast outgrowth was documented from AMT explants. This was not significantly different from unoperated conjunctiva 180° from the site of surgery. Fibroblast outgrowth at the late time point was significantly higher from the peri-AMT biopsies than from unoperated conjunctiva (*P* = 0.032).

Histologic State of Amniotic Membrane. AMTs remained intact on histologic examination after 14 days but were associated with marked granulomatous inflammation, with giant cell formation. After 36 days, the ocular surfaces remained clinically intact, but beneath the epithelium, lysis of AMTs was noted histologically (Fig. 5).

TABLE 2. Fibroblast Outgrowth from Explants in Tissue Culture

	Biopsy Site*			
	1†	2‡	3§	4
Early				
No. of biopsies	24	24	14	12
Fibroblast outgrowth (cm ²)	0.205 ± 0.061	0.283 ± 0.096	0.0 ± 0.0	0.331 ± 0.166
Significance as compared with site 1¶		0.50	0.003	0.39
Late				
No. of biopsies	24	24	12	12
Fibroblast outgrowth (cm ²)	0.057 ± 0.017	0.234 ± 0.076	0.032 ± 0.029	0.022 ± 0.013
Significance compared with site 1¶		0.032	0.46	0.096
Overall				
No. of biopsies	48	48	26	24
Fibroblast outgrowth (cm ²)	0.131 ± 0.033	0.258 ± 0.061	0.015 ± 0.013	0.176 ± 0.088
Significance compared with site 1¶		0.07	0.04	0.56

Values are mean ± SE.

* See Figure 2.

† Conj. 180° from trab. site (unoperated conjunctiva).

‡ Peri-AMT conjunctiva.

§ AMT.

|| Conjunctival bleb biopsy from control trab.

¶ *P* value calculated from Student's *t*-test.

DISCUSSION

The success of glaucoma filtration surgery is often hampered by excessive fibrosis, which obliterates the subconjunctival

space in the vicinity of the filtration site reducing the area available for aqueous drainage and absorption.⁴⁰⁻⁴² Antifibrotic drugs inhibit this activity, thereby improving surgical success, but there is widespread concern that these drugs result in an increase incidence of postoperative complications.²⁸

A different approach to the reduction of postoperative scarring after glaucoma filtration surgery would be to replace conjunctiva and tenon's capsule in the vicinity of the filtration site with a tissue that has a lower propensity to scar. Suitable candidates should be biocompatible and non-immunogenic, as well as semipermeable to water. These requirements are similar to the biological characteristics of amniotic membrane. Placental membranes were first reported to assist healing of exposed body surfaces in 1912.⁴³ When amniotic membrane without chorion is used, healing occurs with less scarring than with primary healing alone. A number of studies have reported similar findings when amniotic membrane is used in ocular surface reconstruction.^{29,30,33,35,44} These effects are mediated via an influence on conjunctival epithelial and subconjunctival fibroblast function, promoting epithelial maturation,^{45,46} and down-regulating fibrogenic TGF- β signaling and myofibroblast differentiation.^{36,47} Finally, amniotic membrane is also relatively permeable to water.³⁷

In this study, a trans-scleral cannula was used to prevent scleral healing. This extra step prevents scleral closure, which would otherwise occur at an early stage in the rabbit model. In the absence of scleral closure as a confounding factor, bleb failure results largely from subconjunctival fibrosis and bleb survival time can be used as an index of the subconjunctival healing response.

AMT was observed to form satisfactory drainage blebs. The time to complete epithelialization of the AMT bleb (11.2 ± 2.5 days, mean \pm SD) was longer than would normally be expected for conjunctiva, but this did not appear to be of clinical importance and was also comparable to epithelialization times reported with other uses of AMT. The two cases of early leakage, both from the limbal edge, highlight a potential problem when attempting to achieve a watertight seal from suturing avascular tissue. This was corrected in later cases by advancing the AMT edge over the limbus onto peripheral cornea




FIGURE 5. Histology and fibroblast outgrowth. (A and B) Section of amniotic membrane (early time point) demonstrating intact membrane with immature epithelialization and underlying inflammatory reaction (periodic acid-Schiff [PAS]). (C) Conjunctiva from control bleb (early time point) demonstrating minimal underlying inflammation (PAS). (D) Amniotic membrane (late time point) with considerable inflammation and lysis of amniotic membrane (PAS). (E) Amniotic membrane explant after 14 days in tissue culture. There is no fibroblast outgrowth. (F) Conjunctival explant after 14 days in tissue culture showing considerable fibroblast outgrowth. Magnification, (A, D) $\times 200$; (B) $\times 400$; (C) $\times 100$.

and adding extra sutures. There were no episodes of bleb-related infection, intraocular hemorrhage, or sequelae of hypotony observed during the study period. One eye had a low IOP at the time of harvesting. This was attributable to a leak as discussed above.

AMT filtration procedures were shown to have longer survival than control procedures in terms of IOP reduction (Fig. 4). This achieved statistical significance at the middle time point (Table 1). Exclusion of the two cases with persistent bleb leakage from the analysis increased the *P* value slightly (*P* = 0.027 for absolute reduction and *P* = 0.018 for percentage reduction) but did not affect significance at the 95% confidence level.

It is interesting that the IOP reduction in the control filtration group was lower in the middle time point when compared with the previous and subsequent time points. However, closer examination of the data revealed that by chance a disproportionate number of early failures had been harvested at day 14, thereby influencing the IOP level at the middle (days 11–16) but not the late (days 28–38) time point. There was no hypertensive phase noted in these animals.

The observation of significantly lower fibroblast outgrowth in tissue culture from explanted AMT biopsies is a likely explanation for the improved duration of survival. Previous studies have shown that AMT has the ability to downregulate fibroblast activity chiefly through an effect on TGF- β function. We consider this model to represent, as closely as possible, the effects of subconjunctival fibrosis on filtration function rather than scleral closure because of prevention of the latter by the indwelling trans-scleral cannula. Scleral closure would otherwise occur early in the rabbit.

Histologically, amniotic membranes were found to be intact after 2 postoperative weeks, whereas those examined at the end of the study period showed significant granulomatous inflammation with giant cell formation. This finding was also reflected in the significantly higher fibroblast outgrowth in tissue culture at the late time point from peri-AMT conjunctival biopsies. We presume the observed inflammatory response was because of the xenogenic nature of the human AMT used in rabbits. Similar findings have not been reported in previous studies in which human to human transplants have been used.

There are two potential areas where we consider that an alternative low-healing tissue might be of use in filtration surgery. In certain first trabeculectomies where there is deemed to be a high risk of failure or in repeat trabeculectomies, a low-healing tissue might obviate the need for antifibrotics. The second is in the revision of leaking or dysesthetic filtration blebs in patients who have previously undergone filtration surgery. Conventional revision of such blebs involves advancement, rotation, or autografting of existing conjunctiva but is often accompanied by an exaggerated subconjunctival fibroblastic response and potentially filtration failure with loss of IOP control.⁴⁸ An alternative tissue might be useful where a muted wound healing response would reduce the risk of filtration failure after surgical revision. In common with the use of antifibrotic agents, the indications for the use of such tissue should be balanced against the potential risk of later leakage and other late bleb-related complications. The two cases of early leakage may indicate a potential problem when translating this type of study into clinical practice, and we have recently reported a problem with late leakage when using AMT in the repair of leaking glaucoma filtration blebs.⁴⁹ An important difference between these two studies is the prior exposure to antiproliferatives of the patients in the latter study.

Estimating the potential for late filtration bleb leakage would be problematic in the rabbit model. The rapid healing response observed in the rabbit model in this study resulted in survival of only one AMT bleb and no control blebs at the end

of the study period. It is unlikely that a longer period of observation would provide better long-term data without further modification of the animal model.

In conclusion, the amniotic membrane transplanted rabbits epithelialized adequately and demonstrated a longer trabeculectomy survival in terms of IOP normalization than control animals, with significantly lower rates of fibroblast outgrowth from the bleb wall in tissue culture. Two cases were complicated by delayed healing, but exclusion of these cases did not reduce the significance of the improvement in bleb survival. These results suggest that amniotic membrane may be an appropriate tissue to use in selected cases of glaucoma filtration surgery. However, the disadvantage of a muted healing response might be a higher risk of leakage after surgery.

References

1. Rockwood EJ, Parrish RKII, Heuer DK, et al. Glaucoma filtering surgery with 5-fluorouracil. *Ophthalmology*. 1987;94:1071–1078.
2. Ophir A, Ticho U. A randomized study of trabeculectomy and subconjunctival administration of fluorouracil in primary glaucomas. *Arch Ophthalmol*. 1992;110:1072–1075.
3. Whiteside-Michel J, Liebmann JM, Ritch R. Initial 5-fluorouracil trabeculectomy in young patients. *Ophthalmology*. 1992;99:7–13.
4. Liebmann JM, Ritch R, Marmor M, Nunez J, Wolner B. Initial 5-fluorouracil trabeculectomy in uncomplicated glaucoma. *Ophthalmology*. 1991;98:1036–1041.
5. Wilson RP, Steinmann WC. Use of trabeculectomy with postoperative 5-fluorouracil in patients requiring extremely low intraocular pressure levels to limit further glaucoma progression. *Ophthalmology*. 1991;98:1047–1052.
6. Egbert PR, Williams AS, Singh K, Dadzie P, Egbert TB. A prospective trial of intraoperative fluorouracil during trabeculectomy in a black population. *Am J Ophthalmol*. 1993;116:612–616.
7. The Fluorouracil Filtering Surgery Study Group. Five-year follow-up of the fluorouracil filtering surgery study group. *Am J Ophthalmol*. 1996;121:349–366.
8. Smith MF, Sherwood MB, Doyle JW, Khaw PT. Results of intraoperative 5-fluorouracil supplementation on trabeculectomy for open-angle glaucoma. *Am J Ophthalmol*. 1992;114:737–741.
9. Doyle JW, Sherwood MB, Khaw PT, McGorray S, Smith MF. Intraoperative 5-fluorouracil for filtration surgery in the rabbit. *Invest Ophthalmol Vis Sci*. 1993;34:3313–3319.
10. Chen CW. Enhancement of intraocular pressure controlling effectiveness of trabeculectomy by local application of mitomycin-C. *Trans Asia Pacific Acad Ophthalmol*. 1983;9:172–177.
11. Chen CW, Huang H-T, Bair J-S, Lee C-C. Trabeculectomy with simultaneous topical application of mitomycin-C in refractory glaucoma. *J Ocul Pharmacol*. 1990;6:175–182.
12. Palmer SS. Mitomycin as adjunct chemotherapy with trabeculectomy. *Ophthalmology*. 1991;98:317–321.
13. Skuta GL, Beeson CC, Higginbotham EJ, et al. Intraoperative mitomycin versus postoperative 5-fluorouracil in high-risk glaucoma filtering surgery. *Ophthalmology*. 1992;99:438–444.
14. Mermoud A, Salmon JF, Murray AD. Trabeculectomy with mitomycin C for refractory glaucoma in blacks. *Am J Ophthalmol*. 1993;116:72–78.
15. Kitazawa Y, Kawase K, Matsushita H, Minobe M. Trabeculectomy with mitomycin: a comparative study with fluorouracil. *Arch Ophthalmol*. 1991;109:1693–1698.
16. Katz GJ, Higginbotham EJ, Lichter PR, et al. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. *Ophthalmology*. 1995;102:1263–1269.
17. Singh K, Egbert PR, Byrd S, et al. Trabeculectomy with intraoperative 5-fluorouracil versus mitomycin C. *Am J Ophthalmol*. 1997;123:48–53.
18. Shields MB, Scroggs MW, Sloop CM, Simmons RB. Clinical and histopathologic observations concerning hypotony after trabeculectomy with adjunctive mitomycin C. *Am J Ophthalmol*. 1993;116:673–683.

19. Nuyts RMMA, Felten PC, Pels E, et al. Histopathologic effects of mitomycin C after trabeculectomy in human glaucomatous eyes with persistent hypotony. *Am J Ophthalmol*. 1994;118:225-237.
20. Hutchinson AK, Grossniklaus HE, Brown RH, McManus PE, Bradley CK. Clinicopathologic features of excised mitomycin filtering blebs. *Arch Ophthalmol* 1997;112:74-79.
21. Yaldo MK, Stamper RL. Long-term effects of mitomycin on filtering blebs. *Arch Ophthalmol*. 1993;111:824-826.
22. Franks WA, Hitchings RA. Complications of 5-fluorouracil after trabeculectomy. *Eye*. 1991;5:385-389.
23. Stamper RL, McMenemy MG, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. *Am J Ophthalmol*. 1992;114:544-553.
24. Zacharia PT, Deppermann SR, Schuman JS. Ocular hypotony after trabeculectomy with mitomycin C. *Am J Ophthalmol*. 1993;116:314-326.
25. Wolner B, Liebmann JM, Sassani JW, et al. Late bleb-associated endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. *Ophthalmology*. 1991;98:1053-1060.
26. Greenfield DS, Suñer IJ, Miller MP, Kangas TA, Palmberg PF, Flynn HW Jr. Endophthalmitis after filtering surgery with mitomycin. *Arch Ophthalmol*. 1996;114:943-949.
27. Higginbotham EJ, Stevens RK, Musch DC, et al. Bleb-related endophthalmitis after trabeculectomy with mitomycin C. *Ophthalmology*. 1996;103:650-656.
28. Parrish RK II, Minckler D. "Late endophthalmitis"—filtering surgery time bomb? *Ophthalmology*. 1996;103:1167-1168.
29. Prabhasawat P, Barton K, Burkett G, Tseng SC. Comparison of conjunctival autografts and amniotic membrane grafts for pterygium excision. *Ophthalmology*. 1997;104:974-985.
30. Lee S-H, Tseng SC. Amniotic membrane transplantation for persistent epithelial defects with ulceration. *Am J Ophthalmol*. 1997;123:303-312.
31. Kruse FE, Rohrschneider K, Volcker HE. Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcers. *Ophthalmology*. 1999;106:1504-1510.
32. Chen HJ, Pires RT, Tseng SC. Amniotic membrane transplantation for severe neurotrophic corneal ulcers [In Process Citation]. *Br J Ophthalmol*. 2000;84:826-833.
33. Tsubota K, Satake Y, Ohyama M, et al. Surgical reconstruction of the ocular surface in advanced ocular cicatricial pemphigoid and Stevens-Johnson syndrome. *Am J Ophthalmol*. 1996;122:38-52.
34. Tseng SC, Prabhasawat P, Lee SH. Amniotic membrane transplantation for conjunctival surface reconstruction. *Am J Ophthalmol*. 1997;124:765-774.
35. Tseng SC, Prabhasawat P, Barton K, Gray T, Meller D. Amniotic membrane transplantation with or without limbal allografts for corneal surface reconstruction in patients with limbal stem cell deficiency. *Arch Ophthalmol*. 1998;116:431-441.
36. Tseng SC, Li DQ, Ma X. Suppression of transforming growth factor-beta isoforms, TGF-beta receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. *J Cell Physiol*. 1999;179:325-335.
37. Lloyd SJ, Garlid KD, Reba RC, Seeds EA. Permeability of different layers of the human placenta to isotopic water. *J Appl Physiol*. 1969;26:274-276.
38. Cordeiro MF, Constable PH, Alexander RA, Bhattacharya SS, Khaw PT. Effect of varying the mitomycin-C treatment area in glaucoma filtration surgery in the rabbit. *Invest Ophthalmol Vis Sci*. 1997;38:1639-1646.
39. Khaw PT, Doyle JW, Sherwood MB, Grierson I, Schultz G, McGorray S. Prolonged localized tissue effects from 5-minute exposures to fluorouracil and mitomycin C. *Arch Ophthalmol*. 1993;111:263-267.
40. Maumenee AE. External filtering operations for glaucoma. The mechanism of function and failure. *Trans Am Ophthalmol Soc*. 1960;58:319.
41. Miller MH, Grierson I, Unger WI, Hitchings RA. Wound healing in an animal model of glaucoma fistulizing surgery in the rabbit. *Ophthalmic Surg*. 1989;20:350-357.
42. Skuta GL, Parrish RK II. Wound healing in glaucoma filtering surgery [Review; 197 refs]. *Surv Ophthalmol*. 1987;32:149-170.
43. Trelford JD, Trelford-Saunders M. The amnion in surgery, past and present. *Am J Obstet Gynecol*. 1979;134:833-845.
44. Kim JC, Tseng SC. Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. *Cornea*. 1995;14:473-484.
45. Kurpakus MA, Stock EL, Jones JCR. The role of the basement membrane in differential expression of keratin proteins in epithelial cells. *Dev Biol*. 1996;150:243-255.
46. Meller D, Tseng SC. Conjunctival epithelial cell differentiation on amniotic membrane. *Invest Ophthalmol Vis Sci*. 1999;40:878-886.
47. Lee SB, Li DQ, Tan DT, Meller DC, Tseng SC. Suppression of TGF-beta signaling in both normal conjunctival fibroblasts and pterygial body fibroblasts by amniotic membrane [In Process Citation]. *Curr Eye Res*. 2000;20:325-334.
48. Budenz DL, Chen PP, Weaver YK. Conjunctival advancement for late-onset filtering bleb leaks: indications and outcomes. *Arch Ophthalmol*. 1999;117:1014-1019.
49. Budenz DL, Barton K, Tseng SC. Amniotic membrane transplantation for repair of leaking glaucoma filtering blebs [In Process Citation]. *Am J Ophthalmol*. 2000;130:580-588.